Literature DB >> 21505297

Circulating inflammatory biomarkers can predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome.

Lewis J Haddow1, Oliver Dibben, Mohamed-Yunus S Moosa, Persephone Borrow, Philippa J Easterbrook.   

Abstract

OBJECTIVE: To identify inflammatory biomarker profiles during paradoxical and unmasking tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS), and determine whether differences in biomarkers prior to antiretroviral therapy (ART) predict subsequent development of TB-IRIS.
DESIGN: Case-control study within a cohort of patients initiating ART in South Africa (n = 498).
METHODS: Participants were followed up for 24 weeks for development of TB-IRIS. Plasma samples were collected at baseline and presentation with symptoms. Groups of cases and controls were as follows: pre-ART TB and developed paradoxical TB-IRIS (n = 9); pre-ART TB but no IRIS (n = 12); no pre-ART TB but developed unmasking TB-IRIS (n = 13); no pre-ART TB and no TB or IRIS during treatment (n = 12). Concentrations of 18 cytokines and chemokines, and C-reactive protein (CRP), were measured and compared.
RESULTS: Event samples were drawn a median of 28 days after ART initiation [interquartile range (IQR) 14-56 days]. During paradoxical TB-IRIS events, there were lower median concentrations of interleukin-10 [IL-10; 22.1 (IQR 15.3-34.9) vs. 82.2 (29.4-128.4) pg/ml, P = 0.047] and monocyte chemotactic protein-1 [MCP-1; 27.6 (20.0-29.7) vs. 71.4 (40.6-77.8) pg/ml, P = 0.005], and higher CRP: IL-10 ratio [2.2 × 10³ (1.8-3.4) vs. 0.3 × 10³ (0.2-0.5), P = 0.003] than in controls. Patients who developed unmasking TB-IRIS had higher median pre-ART levels of CRP [25 (8-47) vs. 6 (lower limit of detection, LLD-12) mg/l, P = 0.046] and interferon gamma (IFN-γ) [9.1 (4.4-24.7) vs. 0.9 (LLD-8.7) pg/ml, P = 0.032] than controls.
CONCLUSION: Patients with unmasking TB-IRIS had higher pre-ART levels of plasma IFN-γ and CRP, consistent with preexisting subclinical TB. Paradoxical TB-IRIS was associated with lower levels of biomarkers of monocyte and regulatory T-cell activity, and higher CRP.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21505297     DOI: 10.1097/QAD.0b013e3283477d67

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  23 in total

1.  Immune reconstitution disorders in patients with HIV infection: from pathogenesis to prevention and treatment.

Authors:  C C Chang; V Sheikh; I Sereti; M A French
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

2.  Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study.

Authors:  Shruthi Ravimohan; Neo Tamuhla; Andrew P Steenhoff; Rona Letlhogile; Kebatshabile Nfanyana; Scarlett L Bellamy; Rob Roy MacGregor; Robert Gross; Drew Weissman; Gregory P Bisson
Journal:  Lancet Infect Dis       Date:  2015-02-09       Impact factor: 25.071

3.  Pathogenesis and immune response in tuberculous meningitis.

Authors:  Bini Estela Isabel; Hernández Pando Rogelio
Journal:  Malays J Med Sci       Date:  2014-01

4.  Role of IL-6 in Mycobacterium avium--associated immune reconstitution inflammatory syndrome.

Authors:  Daniel L Barber; Bruno B Andrade; Cortez McBerry; Irini Sereti; Alan Sher
Journal:  J Immunol       Date:  2013-12-11       Impact factor: 5.422

5.  Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection.

Authors:  Francesca Conradie; Andrea S Foulkes; Prudence Ive; Xiangfan Yin; Katerina Roussos; Deborah K Glencross; Denise Lawrie; Wendy Stevens; Luis J Montaner; Ian Sanne; Livio Azzoni
Journal:  J Acquir Immune Defic Syndr       Date:  2011-11-01       Impact factor: 3.731

6.  Emergence of Polyfunctional Cytotoxic CD4+ T Cells in Mycobacterium avium Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients.

Authors:  Denise C Hsu; Kimberly F Breglio; Luxin Pei; Chun-Shu Wong; Bruno B Andrade; Virginia Sheikh; Margery Smelkinson; Constantinos Petrovas; Adam Rupert; Leonardo Gil-Santana; Adrian Zelazny; Steven M Holland; Kenneth Olivier; Daniel Barber; Irini Sereti
Journal:  Clin Infect Dis       Date:  2018-07-18       Impact factor: 9.079

7.  Associations of Plasma Cytokine and Microbial Translocation Biomarkers With Immune Reconstitution Inflammatory Syndrome.

Authors:  Varghese George; Linda Harrison; Margaret Roach; Xiao-Dong Li; Camlin Tierney; Margaret A Fischl; Judith Aberg; Pablo Tebas; David M Asmuth; Richard B Pollard; Catherine Godfrey; Savita Pahwa
Journal:  J Infect Dis       Date:  2017-11-27       Impact factor: 5.226

8.  TB-IRIS after initiation of antiretroviral therapy is associated with expansion of preexistent Th1 responses against Mycobacterium tuberculosis antigens.

Authors:  Ramachandran Vignesh; Nagalingeswaran Kumarasamy; Andrew Lim; Suniti Solomon; Kailapuri G Murugavel; Pachamuthu Balakrishnan; Sunil S Solomon; Kenneth H Mayer; Chinnambedu R Swathirajan; Ezhilarasi Chandrasekaran; Ambrose Pradeep; Selvamuthu Poongulali; Constance A Benson; Martyn A French
Journal:  J Acquir Immune Defic Syndr       Date:  2013-11-01       Impact factor: 3.731

Review 9.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

10.  Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164.

Authors:  Philip M Grant; Lauren Komarow; Michael M Lederman; Savita Pahwa; Andrew R Zolopa; Janet Andersen; David M Asmuth; Sridevi Devaraj; Richard B Pollard; Aaron Richterman; Sudheesh Kanthikeel; Irini Sereti
Journal:  J Infect Dis       Date:  2012-09-21       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.